Bristol Myers Squibb is paying $600 million up front to begin a 13-drug collaboration with Hengrui Pharma spanning oncology, hematology, and immunology. That tops a 12-drug pact GSK inked last year with Hengrui, a China-based company that has global growth ambitions.
The Phase 3 results in China are encouraging for Kailera Therapeutics, which holds rights to the molecule in the rest of the world. The startup is preparing a global clinical development program for this drug, a once-weekly injectable GLP-1 and GIP receptor agonist.
By reducing administrative burden and redesigning workflows around human needs, it creates space for what matters most: connection between clinicians and patients.